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RISK ATTITUDE: ASSOCIATION WITH 
MAGNITUDE OF RISK AND
PATIENT CHARACTERISTICS
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 Decision analytic models typically
compare strategies using expected values, which assumes





 Examine how risk attitude is affected by the
magnitude of the risk involved, and by the sociodemo-





of 5 related standard gambles was created. In all of them
the patient has an asymptomatic disease that will cause
painless death in 5 years. The only treatment is a pill that
only works if taken immediately. If successful, the patient
will live for 15 years. The 5 scenarios correspond to 0–4
years until death in the event of treatment failure. The
probability of failure was varied to establish the break-
even point. The expected break-even point was calculated
based on expected values. Risk attitude was measured us-
ing the Risk Attitude Ratio (RAR), the ratio of the indi-






 1 indicates perfect risk neutrality, with
lower values indicating risk adversity. Regression models
for each scenario were constructed for RAR, with regres-
sors based on age, race, sex, education, income and mari-
tal status. Additionally, a hierarchical linear model was




167 people were surveyed. Significant risk adversity was
observed in all scenarios. Mean break-even points ranged
from .07–.35. When treatment failure meant immediate
death, risk aversity was great with no statistically signifi-
cant associations. As time until death increased, RAR in-
creased (less risk averse) and was associated with sex,
race and marital status. These associations were upheld
in the overall model. Males and the previously married






 Risk attitude varies according to
the specifics of the gamble as well as sociodemographics.
Assumptions of risk neutrality may be particularly poor




THE IMPACT OF HOSPITAL COSTING 



































 In multinational trials, hospital costing is
estimated by assigning diagnosis- and country-specific
unit cost estimates to hospitalizations. Using this method-
ology, the standard error for hospitalization costs is un-
derestimated. Our objective is to expand methods for in-
ternational hospital costing to increase the validity of
hospitalization costs and to explore the effects of using





 In this analysis, ‘standard’ costing methodology as-
signs a fixed cost to each hospitalization. The ‘expanded’
methodology involves: (1) using DRG weights to adjust
country-specific cost estimates for diagnoses for which
cost data were not collected; (2) differentiating between
costs that occur on the day of admission and all remain-
ing hospital days; and (3) adjusting cost estimates by
length of stay for each hospitalization. Using data from a
subset of placebo-treated patients enrolled in a multina-
tional study of a new treatment for heart failure, we com-
pared estimates of total hospitalization costs using ‘stan-





hospitalization costs were estimated for 200 patients who





 1.42). Using ‘standard’ and ‘expanded’
methods, average total costs were $5,911 and $5,881, re-
spectively. The corresponding standard errors were $269
and $417, an increase of 55% resulting in a loss of
 








 0.05, 2-sided t-test, and a $500 difference in costs,
one would have 25.7% power using ‘standard’ costing
methods but only 13.5% when using ‘expanded’ meth-
ods. With a $1,000 difference, one would have 74.5%





results of a cost comparison between treatment strategies
can be affected by the methodology used to calculate
costs. Studies that consider the intensity of hospital care,
or that consider the variability in resource utilization, re-
quire a larger sample size than studies that don’t consider








RESPONSE BIAS AMONG LIKELY CLINICAL 
TRIAL PARTICIPANTS
 
McDonnell DD, Donohue JA
 




 To understand the demographic, attitudi-
nal, behavioral, and clinical characteristics of people who




Analyses were based on a 12-page questionnaire mailed
to U.S. adults in 2000. A total of 21,986 responses were
received. Respondents were nationally representative
based on gender, age, race, and geographic region; results
were subsequently weighted and projected to the U.S.
population. Participants were asked if they had ever par-
ticipated in a clinical trial and whether they would ever





who never participated in a clinical trial, 33% said they
would strongly consider participating in the future. This
group differed in some dramatic ways from the 26% who
said they would definitely not consider participating in a
clinical trial. For example, those who would participate
were more likely to be female (55% v. 49%), younger
(43 v. 47 years), and white (77% v. 70%). Behaviorally,
likely participants were more likely to drink alcohol
(64% v. 55%), smoke (27% v. 22%), visit physicians
(4.0 v. 3.6 visits in six months), and use the internet for
health care information (13% v. 6%). Attitudinally,
those willing to participate were more likely to harbor al-
ternative health care attitudes (e.g., “would try acupunc-
ture” 38% v. 17%) and less likely to be satisfied with
their current medical care (39% v. 47%). Clinically, they
were more likely to be diagnosed with a range of comor-
bid medical conditions such as depression (15% v. 6%),





 People who are likely to partici-
pate in clinical trials look, think, and behave differently
than those who are not likely to participate. Trail design
and analysis should consider these differences and their




































 It is well documented that resource con-
sumption and costs vary across settings. Unit costs can
also vary. Using consistent cost-finding methods across
and within five Western European (WE) countries unit
costs of cardiovascular procedures were compared to ex-




Unit cost data were collected from fee schedules, national
averages and selected individual institutions. A bottom-
up costing approach was used in hospitals based upon a
definition of resources consumed for procedures. Hospi-
tal daily rates were calculated from an allocation of over-
head accounts and a basic package of services such as
nursing, housekeeping, dietary and pharmacy services.
Costs were obtained in the local currency and converted




 Unit cost variation was ob-
served within and across countries. UK costs for percuta-
neous transluminal coronary angioplasty (PTCA) in 13
centers ranged between 1380 and 2700 Euros, 0.75–1.5
times the median. Inter-country cost variation for the
same procedure ranged between 1850–4000 Euros, 0.60–
1.3 times the median. Daily hospital general ward rates
vary inter-country between 0.8 and 1.6 times the median,
comparable to within country variation. Physician ambu-
latory visit costs from fee schedules that may not reflect
actual costs were standard within country but varied
across countries (0.5–1.2 times the median of 18 Euros).
When applied to a consistent set of resources, differences
in costs resulted in widely varying cost-effectiveness (CE)





ble unit costs within countries is difficult. Center-specific
costing is most reliable, but expensive and must be repre-
sentative for submissions to national level health authori-
ties. With standardized costing methods, the differences
observed here cannot be explained by differences in ac-
counting. Extreme care must be taken when transferring
the results of CE analyses between centers, especially be-
tween countries.
 




COST-EFFECTIVENESS OF AIRLINE 
DEFIBRILLATORS: IS PEACE OF MIND MORE 





























 Airline passengers are particularly vulner-
able to the effects of cardiac arrest due to a lack of access
to emergency medical services. To offset this isolation,
airlines are installing automated external defibrillators
(AEDs) on aircraft. Our objective was to measure the
cost-effectiveness of airline AED programs and estimate





analytic model was constructed to estimate the clinical
and economic effects of airline AEDs. Inputs were ob-
tained from published data and the FAA. Utility esti-
mates were derived from cardiac arrest survivors. Sensi-
tivity analyses evaluated changes in AED cost and
probability of cardiac arrest. Since AEDs may provide
utility gains through “peace of mind” for passengers not
experiencing a medical event, the impact of this added




AEDs on commercial aircraft cost an incremental $5.16






ditional $162,000 per QALY gained (16 quality-adjusted
minutes per flight). Sensitivity analysis of event proba-
bilities and cost inputs did not substantially change the
results. However, the cost-effectiveness of AEDs was sig-
nificantly enhanced by the inclusion of utility gain experi-
enced by passengers from increased peace of mind. While
the magnitude of this benefit is unknown, an incremental
increase of .003 in utility over the flight duration would
reduce the incremental cost-effectiveness of AEDs to less





model estimated that when the benefits of on-board
AEDs are limited to patients experiencing medical events,
the incremental cost-effectiveness is inferior to most rec-
ommended medical interventions. However, if passengers
gain utility from knowing an AED is on the aircraft, then
these incremental expenditures may be justified. Utility
gains from “peace of mind” may have significant impli-
cations in determining the value of health care interven-





ANALYSIS OF THE IMPACT OF ASSISTIVE 
LIVING DEVICES ON SELF-ASSESSED HEALTH 
STATUS RATING
 
Rodney AB, Xiao H, Robertson T
 




 Persons with limitations in Activities of
Daily Living (ADLs) generally report a greater sense of
independence when they have the use of assistive devices.
Insurance companies have traditionally been reluctant to
cover the cost of such devices, considering them to be
non-essential equipment. Although the economic cost
savings associated with a decrease in the need for exter-
nal caregivers and institutionalization are calculable, the
psychological benefits arising from this greater degree of
independence seen in patients who use assistive devices
tends to be overlooked. Therefore the main objective of
this project was to determine the impact of assistive living




Medical Expenditure Panel Survey (MEPS) Household
Component file 1998 P2R3/P3R1 was utilized for this
project. The initial pool of 25,000 cases was narrowed
using the inclusion criteria whereby all subjects must be
65 years or older, and have coded that they possessed one
or more physical disabilities or limitations. This led to a
final sample size of 1,025. Information on demographics,
socioeconomic status and level of disability was extracted
from the database for these patients. Multiple regression
analysis was conducted with self-rating of health status
serving as the dependent variable. The primary indepen-
dent variable of interest was use or non-use of assistive
living devices. Secondary independent variables included:
marital status, sex, age, race, educational level, physical





 Use of assistive devices, race, age, some forms of
physical limitations and levels of education were signifi-




 0.05). Marital status and gender





of assistive devices does have an impact on the way in
which individuals with limitations and disabilities view
their health status and therefore may be important con-




THE DIAGNOSTIC ACCURACY OF 18FDG-PET 
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 Positron Emission Tomography with 18F-
fluorodeoxyglucose (FDG-PET) is a new nuclear imaging
technique that can detect recurrent or metastatic thyroid
carcinomas. We conducted a systematic review to deter-
mine the diagnostic accuracy of FDG-PET in patients





 Two unblinded reviewers independently selected,
extracted and assessed data from relevant literature. In-
cluded studies were prospective or retrospective with 10
human subjects or more that evaluated the accuracy of
FDG-PET in follicular and papillary thyroid cancer. Re-
views, case reports, editorials, letters, and comments
were excluded. The methodological quality of the in-
cluded studies was assessed by the criteria for diagnostic
tests recommended by the Cochrane Methods Group on
Screening and Diagnostic Tests. A qualitative analyse was
conducted to assess the value of FDG-PET in thyroid car-
cinoma. The rating system consisted of four levels of sci-













the fourteen included studies were considered of level 3
evidence. The other twelve studies provided level 4 evi-
dence. Most prevalent methodological flaws regarded va-
lidity of reference tests and blinding of test interpretation.
The overall conclusion in these studies was that FDG-
PET appeared beneficial in patients with elevated thyro-




In conclusion, although FDG-PET may solve clinical prob-
lems in selected patients suspected of recurrent thyroid
cancer, the present evidence does not allow for imple-
mentation of a routine diagnostic algorithm. Future stud-





INCLUSION OF INDIRECT COST IN ECONOMIC 
OUTCOMES ANALYSES OF MEDICAL DEVICES: 
HOW IMPORTANT IS IT?
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 To evaluate the impact of indirect cost
(due to absence from work, disability, mortality) in eco-






dures using devices to conventional open surgery. Indi-
rect cost savings benefit patients, employers and society




 We searched the literature and identified
studies in which “indirect cost”, “convalescence” or
“work loss” were included in the analysis. All articles
published since 1990 on menorrhagia (laparoscopic hys-
terectomy/endometrial ablation versus open hysterec-
tomy), Gastroesophageal Reflux Disease (GERD) (lap-
aroscopic versus open Nissen fundoplication), and
coronary artery disease (Percutaneous Transluminal Cor-
onary Angioplasty (PTCA) versus Coronary Artery By-
pass Graft (CABG) surgery) were reviewed. Key informa-
tion abstracted included: days of work lost, direct and
indirect cost estimates, costing methodology, and follow-
up period. The percentage impact, measured as the
change in the difference between the total cost of open
surgery compared to the less-invasive procedure due to




The review produced 11 articles on menorrhagia, 5 on
GERD, and 5 on coronary artery disease. There were
large differences in the average days of work loss between
open surgery and less-invasive procedures; 21 days for
laparoscopic versus 40 days for open hysterectomy, 15
days for laparoscopic versus 35 days for open fundopli-
cation, and 27 days for PTCA versus 74 days for CABG.
The percentage impact or difference in total cost due to





 Cost savings associ-
ated with minimally invasive surgery compared to open
surgery are significantly increased when indirect costs are
included in the assessment. Future economic outcome
studies should attempt to include indirect cost measures
to fully capture the benefits of devices and minimally in-
vasive procedures.
 































 The issue of whose values count in the
evaluation of health interventions is central to decision-
making in all health care systems. Within the health ser-
vices research community there is a degree of consensus
that population-based preference weights should be used
as the quality-adjustment factor in determining the value
of health outcomes. However, previous research indicates
an inverse, graded relationship between socioeconomic
status (SES) and an individual’s own health. If SES is also
found to influence the valuation of hypothetical health
states, then this could prove to have significant conse-




Values for hypothetical health states defined by EQ-5D
(a generic measure of health-related quality of life) were
collected from a representative survey of the UK general
population. 2,997 individuals used time trade-off (TTO)
methods to value these EQ-5D health states. Information
on each respondent included age, gender, social class and
educational attainment. TTO values were bounded and
non-normally distributed necessitating methods such as





 Education and social class as
proxies for SES were significant predictors of the mean
values for hypothetical health states. Their influence on
health state valuation appears to act through their inter-
action with the mobility and self-care dimensions of the
EQ-5D. This relationship persists after adjustment for re-




Valuation of hypothetical health states appears related to
SES. This has implications for cost-effectiveness analysis
since valuations from one population with a particular
SES distribution may not be applicable for health policy
and medical decision-making in other populations. The
relationships between SES and health state valuation merit
further investigation, in particular to examine the impact




LOGICAL CONSISTENCY AND THE VALUATION 






















 It is widely held that values of the general
public should be used in the evaluation of health care.
Surveys designed to record such values involve the partic-
ipation of individuals with different health experiences
and with different socioeconomic backgrounds. The tech-
nical performance of these participants is likely to vary as
a function of these factors, for example the logical consis-
tency of responses is often associated with socioeconomic
status. This paper examines the relationship between log-
ical consistency and respondent health using US survey





 A standardised ques-
tionnaire was used to elicit valuations for EQ-5D health
states in a postal survey conducted by Johnson et al





 905) rated eight states along a visual an-
alog scale from best to worst imaginable health. A logical
ordering is defined for 23 unique pairs of states in that
one state dominates the other over all 5 dimension of the
EQ-5D. A logical inconsistency was noted when a re-
spondent assigned a lower value to the “better” state in
such a pair. Censored regression models were used to as-
sess the relationship between consistency and respondent
health. We tested the robustness of these findings using














 From the best imag-
inable state, each 20-point decrement in respondent’s
self-rated health status yielded significantly greater incon-
sistency in their valuation of EQ-5D health states con-
trolling for age and sex. Inclusion of education and in-





 Respondents in poor health
demonstrate greater difficult in valuing health states in a
logically consistent manner. Censoring survey data to re-
move inconsistent respondents may violate the principle
of using representative population values in evaluating




QUALITY OF LIFE IN PRODUCT LABELING:
























Pfizer Pharmaceuticals Group, Ann Arbor, MI, USA
 
Increasingly over the past several years, quality of life and
patient-reported outcomes data have been submitted as
part of NDA and sNDA packages to US and Interna-
tional regulatory agencies. These data provide important
information to prescribing clinicians and patients regard-




 To evaluate the marketed drugs with the




 A search of the Physician Desk Reference
database was conducted to identify those products that
included the term “quality-of-life” (QoL) within the Phy-
sician Package Insert. The Summary Basis of Approval
(SBA) of each product was reviewed to evaluate the re-
search processes followed, use of psychometrically vali-
dated instruments, and the final resulting language at-




Twenty-two products referencing the term “quality-of-
life” in the product labeling were identified. FDA ap-
proval of these products occurred mainly in the years
from 1982 to 2000 with increasing frequency of QoL in-
clusion in recent years. Upon SBA review we found the
majority of the products (13/22) utilized a validated in-
strument during clinical investigations. Only one of the
22 SBAs specifically described and discussed the issue of
instrument validation. In the early years approved label-
ing claims included more broad, sweeping terminology
when describing QoL results. In more recent, cases, ap-
proved QoL labeling claims were more narrowly defined
and more rigorously worded with respect to trial results




Over the course of the time, the approach has become
more rigorous resulting in a more refined QoL research
process. These findings have demonstrated that the use of
QoL descriptive data has increased, particularly a greater
degree of comprehensive information pertaining to QoL
instruments, research, and data can be found in the SBAs.
Hence, more relevant and specific QoL information is




QUALITY OF LIFE MESSAGES IN PRESCRIPTION 
DRUG ADVERTISEMENTS IN LEADING MEDICAL 
JOURNALS, 1990–99
 
Zivin K, Neumann P
 




 The use of health-related quality of life
(HRQL) claims in drug promotions is under active dis-
cussion by the pharmaceutical industry, the FDA, and
other stakeholders. However, the extent to which phar-
maceutical companies have previously promoted HRQL
messages in advertisements in medical journals, and




 We performed a content analysis of all
pharmaceutical advertisements appearing in three general
medical journals (AIM, JAMA, and NEJM), and three
specialty journals (Circulation, Gastroenterology, and
Neurology) in January, July, and October annually from
1990–1999. Two reviewers analyzed each advertisement
for the presence and type of HRQL content, and for sup-
porting evidence. We distinguished explicit HRQL
claims, which used words, such as “quality of life or “pa-
tient satisfaction,” from implicit claims, which we de-
fined broadly as pictures implying improved physical,





judged that HRQL messages appeared in 520 (24.3%) of
2142 advertisements examined. Advertisements with
HRQL content increased from 1990–94 to 1995–99




 0.0001). 56% of HRQL con-
tained implicit messages only, followed by ads that used
both implicit and explicit messages (35%), and ads con-
taining explicit messages alone (9%). Overall, few ads
(12%) contained any clear supporting evidence. Mes-
sages that implied or stated improved overall well-being
or mental health were most common (78% of all HRQL
ads), followed by enhanced physical or social functioning









 Advertisements conveying HRQL mes-
sages are used frequently by drug manufacturers in medi-
cal journals, and are increasing over time. In the future,
researchers should better define HRQL, and probe more
deeply into what comprises substantiating evidence, per-
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AMONG HEPATITIS C-INFECTED MEMBERS IN A 
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Approximately 2.7 million Americans have active Hepa-
titis C infection. Combination therapy with ribavirin and
interferon alfa-2b has emerged as the treatment of choice
for Hepatitis C. OBJECTIVES: To determine if the pre-
scribing of combination therapy differed among ethnic
groups in Hepatitis C-infected members during calendar
year 1999 in a Medicaid MCO. METHODS: Hepatitis
C-infected patients were identified from a database of
continuously enrolled members of an inner-city Medicaid
MCO in Philadelphia using ICD-9 codes indicative of
Hepatitis C (070.41, 070.44, 070.51, 070.54, 571.40,
571.41, V02.60, V02.62). From this population, mem-
bers who received combination therapy with ribavirin
and interferon alfa-2b were identified and demographic
information was obtained. Variation in the prescribing of
combination therapy among ethnic groups was assessed
using a Chi-square test. RESULTS: From a cohort of
73,869 members, 395 members (0.535%) had an ICD-9
code for Hepatitis C. Of those, 60 members had phar-
macy claims for combination therapy during 1999. These
members aged from 23 to 64 years (mean age 5 45.0 yrs;
SD 5 7.6). Based on the ethnic distribution of the 395
members with an ICD-9 code for Hepatitis C, 8.4% (16/
191) of African-Americans were prescribed combination
therapy compared with 23% (28/122) of Caucasians,
22.7% (15/66) of Latinos and 14.3% (1/7) of Asian-
Americans. A statistically significant difference in the pre-
scribing of combination therapy was noted among ethnic
groups (p , 0.05). CONCLUSIONS: Within this Medic-
aid MCO, a disproportionately low percentage of Afri-
can–American members received combination therapy
for Hepatitis C during 1999. It is unknown whether this
was due to a disproportionate number of contraindica-
tions in this group, inequitable prescribing habits of phy-
sicians, cultural barriers preventing consent for treat-
ment, or noncompliance with obtaining the medication.
Further investigation is needed to determine why this dis-
parity exists so that differences in treatment among eth-
nic groups may be minimized.
HP2
THE ROLE OF OUTLIER PAYMENTS IN 
MEDICARE PATIENTS WITH SEVERE SEPSIS
Cooper LM1, Linde-Zwirble WT2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Health Process 
Management, Owings Mills, MD, USA
INTRODUCTION: Medicare is required to set outlier
threshold so that outlier payments are between 5 and 6
percent of total DRG payments to offset extraordinarily
high-cost cases. Severe sepsis (SS) is a condition affecting
patients in many DRGs. High mortality and resource use
in SS patients increases the likelihood of reimbursement
under the outlier mechanism. We explore the role of out-
lier payments for SS in Medicare. METHODS: We exam-
ined all 1999 Medicare discharges age 651 in prospec-
tive payment hospitals. Cost, reimbursement, and outlier
payments were identified for each discharge. SS was iden-
tified by the presence of ICD-9-CM codes for acute organ
failure and bacterial or fungal infection. DRGs were clas-
sified into six groups by post-operative status (medical
and surgical) and by frequency of SS (high risk, high vol-
ume, remaining). RESULTS: Of 9,248,277 records,
384,680 (4%) were reimbursed through the outlier mech-
anism, reflecting 6% of total payments. SS patients repre-
sent 25% of all outliers, with an average cost per outlier
case of $44,724. The average cost for non-sepsis outliers
per case is $35,098. Twenty-two percent of all sepsis
cases are reimbursed as outliers. While overall cases are
reimbursed at 95% of reported costs, SS cases are reim-
bursed at only 85% of costs. SS outliers are reimbursed
at only 70% of reported costs with especially low reim-
bursements for high volume medical SS outlier cases
(54%). Overall, SS high risk medical and surgical cases
are reimbursed at higher levels (103% and 78% respec-
tively). CONCLUSIONS: While severe sepsis cases are
only 4.7% of all Medicare discharges, almost one in four
are outliers. Current outlier payments do not adequately
compensate for the cost of care of most SS patients.
HP3
INCORPORATING CLINICAL OUTCOMES AND 
ECONOMIC CONSEQUENCES INTO DRUG 
FORMULARY DECISIONS: EVALUATION OF 30 
MONTHS OF EXPERIENCE
Atherly DE1, Sullivan SD1, Fullerton DS2, Sturm LL2
1University of Washington, Seattle, WA, USA; 2Regence 
BlueShield, Seattle, WA, USA
BACKGROUND: In January 1998, Regence BlueShield,
a 1.2 million-member health plan, implemented a novel
formulary submission process intended to improve clini-
cal decision-making. The process requires pharmaceutical
manufacturers to submit dossiers that include clinical and
health outcomes data as well as an economic model that
will demonstrate the impact of introducing the product
to the health plan. Since implementation, the process has
not been evaluated. OBJECTIVE: To evaluate the scope
and content of submission dossiers received from January
1998 to June 2000. METHODS: All dossiers received
from January 1998 to June 2000 were collected and re-
viewed. They were evaluated for compliance with the Re-
gence Formulary Submission Guidelines. Data were en-
tered into a spreadsheet for analysis. RESULTS: A total
of 50 dossiers were reviewed. 25 (50%) were received in
year 1, 16 (32%) in year 2, and 9 (18%) in the first six
months of year 3. An economic model was provided in
31 dossiers, increasing from 55% to 78% of dossiers
over the three years. Only 10 models were cost-effective-
ness analyses. The remaining models were budget impact
analyses. Complete clinical information was included in
48%, 63% and 78% of submissions in years 1, 2 and 3
respectively. Dossiers were prepared by one of three
sources: Staff at the manufacturer’s headquarters (68%),
an outside vendor (10%) or a local manufacturer’s repre-
sentative (22%). Unpublished studies, which were specif-
Abstracts 53
ically requested, were included in 18 dossiers, and off-
label information was included in 7. Of the 50 products
submitted, 24 (48%) were added to Formulary. CON-
CLUSIONS: Compliance with the guidelines has im-
proved over the past 30 months. Overall, a majority of
the submissions included complete clinical information
and some type of economic analysis. There remains,
however, significant opportunity for improvement, par-
ticularly in the presentation of economic evaluation data
and the dissemination of unpublished studies.
HP4
ASSESSING LIFESTYLE DRUGS FOR DRUG 
BENEFIT FORMULARIES: A COST-UTILITY 
ANALYSIS OF ORLISTAT AND SIBUTRAMINE 
FOR THE TREATMENT OF OBESITY IN ADULTS
Trakas K1, Oh PI2, Leiter L3, Shear NH2
1University of Toronto, Toronto, ON, Canada; 2Sunnybrook 
and Women’s College Health Science Centre, Toronto, ON, 
Canada; 3St. Michael’s Hospital, Toronto, ON, Canada
Obesity is now recognized as a chronic health condition
instead of a cosmetic or lifestyle issue. Orlistat and
sibutramine are effective weight-loss/weight-maintenance
agents. Insurers argue that the high prevalence of obesity
(i.e., body mass index (BMI)3 30kg/m2), questionable
long-term health benefits, and cost of these drugs make it
unfeasible to cover them. Proponents claim decreases in
obesity’s comorbidities would offset acquisition costs.
OBJECTIVES: To provide evidence for a rational reim-
bursement policy for pharmacological treatments of obe-
sity in adults. METHODS: A Markov decision analytic
model was used to evaluate the cost-effectiveness of orlistat
(120mg TID) and sibutramine (5–20mg QD) relative to
diet and exercise alone. The model analyzed a hypothetical
population of obese, but otherwise healthy 30 year olds
over their lifetime. Estimates of efficacy and tolerance were
derived from a meta-analysis of randomized, placebo-con-
trolled trials of orlistat and sibutramine. The Framingham
Study was used to derive risk-adjusted equations for the in-
cidence of hypertension, dyslipidemia, and DM as well as
the incidence of CV events, CV-attributable death, and
non-CV death. Equations were adjusted for known risk
factors, including BMI. The reference case analysis used the
societal perspective and included both direct and indirect
costs (discount rate, 3%). Costs were derived from the liter-
ature and inflated to year 2000 Canadian dollars (CDN$).
Utilities were derived from a Canadian health survey and
from the literature. Decision index: incremental cost per
quality adjusted life year ($/QALY). A Monte Carlo simu-
lation will be used to perform a sensitivity analyses around:
estimated weight-loss, estimated dropout rates, estimated
weight regain, cost of treatment, and major clinical events.
RESULTS: Results for the base case (i.e., societal view-
point) and third party payer (i.e., Ministry of Health) per-
spectives will be presented and discussed. Emphasis will be
placed on the decision model approach for informing for-
mulary decisions on “lifestyle” drugs.
CANCER
CN1
UTILITIES OF METASTATIC BREAST CANCER 
PATIENTS (PT) TREATED WITH TAXANES 
COMPARED TO UTILITIES OF ONCOLOGY 
NURSES (NUR)
Hauser R1,3, Theriault R2, Wilson J3, Shepherd M3, Lawson K3, 
Koeller J3
1Abt Associates Clinical Trials, Cambridge, MA, USA; 
2University of Texas M.D. Anderson Cancer Center, Houston, 
TX, USA; 3University of Texas, Austin, TX, USA
Cost-utility analysis is rapidly becoming the standard
pharmacoeconomic measure in oncology. In a recent re-
port (JCO, 2000;18:3302), data from 40 published cost-
utility studies were presented in a league table format.
Most of those studies utilized nurses or physicians as
proxies for the pt. in determining utility. OBJECTIVE:
To determine if there is a difference between utility scores
obtained from metastatic breast cancer pt. and oncology
nurses. METHODS: Using eight modified Markov mod-
eled health states (Pharmacoeconomics, 1996; 60:504)
describing metastatic breast cancer; the standard gamble
procedure was utilized to obtain utility scores from 45
patients and 57 oncology nurses. Utility values were mea-
sured on a scale between 0.0 and 1.0. Independent t-tests
were used to test for differences between groups using an
alpha level of 0.05 (2-sided). RESULTS: Significant dif-
ferences were found on all eight modeled health states:
CONCLUSION: These results show that patients have a
higher utility for health than perceived by nurses. These
data leads to the question of whose utility values should
be used for cost-utility analysis in oncology.
CN2
EFFECT OF INCLUDING (VERSUS EXCLUDING) 
FATES WORSE THAN DEATH ON UTILITY 
MEASUREMENT
Franic DM1, Pathak DS2
1The University of Georgia, Athens, GA, USA; 2The Ohio State 











Partial Response (PR) .84 (.11)/.71 (.22) .0001 .06–.20
PR with Severe
Peripheral Edema .78 (.17)/.63 (.24) .0001 .08–.24
PR with Severe
Peripheral Neuropathy .76 (.13)/.56 (.24) .0001 .12–.28
Before Second Line
Treatment Begins .73 (.16)/.59 (.22) .0001 .06–.22
Stable Disease .72 (.15)/.54 (.22) .0001 .11–.26
Late Progressive Disease .63 (.18)/.45 (.25) .0001 .10–.27
Terminal Disease .40 (.26)/.19 (.21) .0001 .13–.31
Sepsis .39 (.25)/.20 (.23) .0001 .09–.28
54 Abstracts
OBJECTIVE: To test impact of including (versus exclud-
ing) health states perceived to be worse than death on
utility measurement using standard gamble (SG) and vi-
sual analogue scale (VAS) methods. METHODS: Face-
to-face interviews were conducted in a convenience sam-
ple of women aged 22 to 50 years with no history of
breast cancer or cancer requiring chemotherapy (n 5
119). Data were collected between March 2000 and June
2000 at a Midwestern University in the US. Subjects were
asked to rate their utility if faced with three hypothetical
breast cancer health states: cure, treatment and recur-
rence. Utility weights were estimated using SG top-down
titration and VAS methods scaled from zero (death) to
one (perfect health). Linear transformation was used to
allow for negative preference weights for health states
worse than death. RESULTS: Unpaired t-test analysis
showed statistically significant greater change in SG (n 5
16) and VAS (n 5 17) utilities for respondents perceiving
cancer recurrence as worse than death than those perceiv-
ing death as least desirable health state (p , 0.05). Mean
change in SG (VAS) utility allowing for health states
worse than death for breast cancer cure versus treatment,
treatment versus recurrence, and cure versus recurrence
were 0.066(0.226), 0.335(0.339), and 0.401(0.564), re-
spectively (n 5 119). Excluding negative utilities from
study resulted in statistically
significant lower mean changes in utility weights (SG n 5
103, VAS n 5 102). CONCLUSION: Most studies typi-
cally measure health preferences excluding health states
perceived as worse than death. Similar to Patrick et al
(1994) results of this study indicate health preference
elicitation methods can be successfully adapted to acquire
negative utilities. Regardless of metric used, both SG and
VAS yield higher changes in weight estimates when nega-
tive utilities are permitted. Addressing negative utilities in
studies could significantly affect QALY estimates in eco-
nomic analyses.
CN3
COST-EFFECTIVENESS ANALYSIS OF 
IRINOTECAN15FU/FA ALONE AS FIRST-LINE 
THERAPY IN ADVANCED COLORECTAL 
CANCER IN THE UK
Brown R1, Sorensen S1, Burrell A2, Bearne A2
1MEDTAP International Inc, Bethesda, MD, USA; 2Aventis 
Pharma, Kent, UK
OBJECTIVES: This study aims to estimate the cost-effec-
tiveness (CE) of irinotecan15FU/FA versus 5FU/FA alone
in the first line treatment of advanced metastatic colorec-
tal cancer from the perspective of the UK National
Health Service. METHODS: A decision tree model was
designed in Excel to track patients through the course of
advanced colorectal disease based upon trial data from
first line management and estimating average survival
and associated resource use. A systematic review and
meta analysis were undertaken for first line treatment
with irinotecan and 5FU/FA and 5FU/FA alone to pro-
vide data on response rate, time to progression, survival
rates (median survival 67.5 weeks versus 55 weeks), drop
out from toxicities, and major adverse events. Medica-
tion costs were based on the British National Formulary
and allow for wastage. Resource utilization for routine
treatment and monitoring, adverse event management,
use of second line chemotherapy, palliative care and
other clinical parameters was elicited from a survey of
five UK oncologists experienced with the therapies.
Wherever possible, acquisition costs from published sources
were applied to the resources. RESULTS: The total costs
including drug, treatment administration, management of
toxicity and of disease progression amounted to £23,825
per patient treated with CPT-1115FU/FA and £18,795
per patient treated with 5FU/FA alone. When the differ-
ence in cost is related to the clinical benefit of irinotecan,
the cost per life year gained was estimated as £20,948.
Sensitivity analysis showed that the analysis was robust
as the CE ratios did not widely vary. CONCLUSION: In
the treatment of advanced metastatic colorectal cancer in
the UK, irinotecan15FU/FA extends survival and the cost
remains within the limits currently accepted for new che-
motherapeutic agents.
CN4
ECONOMIC EVALUATION OF GEMZAR/
CISPLATIN RELATIVE TO OTHER CISPLATIN 
BASED TREATMENTS FOR NON SMALL CELL 
LUNG (NSCLC) CANCER IN THE UK
Botwood N1, McKendrick J1, Aristides M2, Lees M2, 
Maniadakis N3, Wein W3, Stephenson D1
1Eli Lilly, Basingstoke, UK; 2M-TAG, London, UK; 3Eli Lilly, 
Windlesham Surrey, UK
OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is a main treatment op-
tion but its availability in the UK is limited and not con-
sistent across geographical regions. This study reports on
an economic evaluation of Gemzar/cisplatin (GC) relative
to: mitomycin/ifosfamide/cisplatin (MIC), etoposide/
cisplatin (PE) and itomycin/vinblastine/cisplatin (MVP).
These represent standard platinum-containing regimens
that are currently used in the UK. METHODS: The study
perspective is that of the UK-NHS. Data were derived
from comparative clinical trials (Crino et al 1999, Carde-
nal et al. 1997, Costa 2000). Costing is based on: chemo-
therapy, infusion, hospitalisations, visits to health care
professionals and concomitant medications. Resource
utilisation from the trials was combined with unit cost
data from various UK sources. Costs correspond to 2000.
Time horizon for the estimation of costs is one year;
hence discounting was unnecessary. Treatment effective-
ness is measured by overall survival and objective tumour
response. RESULTS: In the first setting the cost-per-
patient on GC was £5,101 and on MIC £4,481. Overall
tumour response rates were 39.6% and 27.6% respec-
tively. Thus, the incremental cost-per-tumour-response of
GC was £5,169. In the second setting, the cost on GC
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was £4,142 compared to £3,762 on PE. Overall tumour
response was 40.6% and 21.9% respectively and progres-
sion-free life years 0.575 and 0.358. Thus, the incremen-
tal cost-per-tumour-response of GC was £2,032 and the
incremental cost-per-progression-free-life-year £1,751. In
the final setting, the cost of GC was £5,084 and of MVP
£4,004. Overall tumour response was 54.0% and 36.7%
and one year survival 36% and 17% respectively. The in-
cremental cost-per-tumour-response of GC was £6,240
and the incremental cost-per-survivor-at-one-year was
£5,681. In extreme changes to underlying variables the
above ratios vary from dominance to a maximum of
£14,000. CONCLUSIONS: These results demonstrate
that Gemzar/cisplatin represents a relatively cost-effective
treatment for NSCLC with ratios comparable of below
those of therapies currently in use within the NHS.
CARDIOVASCULAR DISEASE
CV1
THE VALUE OF COMPLIANCE: EVIDENCE FROM 
TWO PATIENT COHORTS
McGuigan KA, Sokol M, Yao J, Haynes J, Qian Q, Boscarino J, 
Epstein R
Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA
OBJECTIVES: To identify the association between com-
pliance and the direct costs of care for two different clini-
cal patient cohorts. METHODS: Using administrative
claims data from Medstat MarketScan (tm) we assessed
the association between prescription drug compliance
and direct costs of care for two patient groups: a cohort
of non-Medicare patients diagnosed as diabetics (N 5
9960) and second cohort of non-Medicare patients diag-
nosed with congestive heart failure (CHF)(N 5 935).
Since patients who are more compliant tend to be older
and have a greater number of comorbidities, and our goal
was to isolate the association between compliance and
medical care costs, we statistically controlled for differ-
ences in potential confounding variables using OLS re-
gression. Covariates included age, gender, comorbidity
indices (Chronic Disease Score and Charlson-Deyo), and
ICD-9-based severity of illness indicators. Compliance
was defined by calculating % days supply over a period
of one year. Compliance was then converted to 7 ordinal
categories in the regression model in order to identify
dose-response associations or threshold/inflection points.
RESULTS: Among diabetics, those who did not use any
prescription medication showed the lowest total costs of
care. However, among those patients who needed pre-
scription medication to manage their illness, increased
prescription drug costs among the most compliant are
more than offset by decreases in medical care costs, for
an estimated return on investment (ROI) of more than
two-fold. A similar, but stronger, pattern was found
among patients with CHF where the estimated ROI was
three-fold or greater. CONCLUSIONS: For some medi-
cal conditions, the additional costs associated with in-
creased compliance may be offset by lower medical costs,
resulting in an ROI greater than one.
CV2
INDIRECT COMPARISONS OF DRUGS USING 
META-ANALYSIS: VALIDATION OF RESULTS
Ross SD1, Klawansky S1, Allen IE2
1MetaWorks, Medford, MA, USA; 2Babson College, Wellesley, 
MA, USA
OBJECTIVES: Health care decision-makers need more
head-to-head drug comparison trials. Industry rarely
sponsors such studies, preferring placebo comparators.
We present an example of using meta-analysis for an in-
direct comparison of 2 drugs, with the results subse-
quently validated in a direct comparison trial. METH-
ODS: The drugs for comparison were abciximab and
tirofiban, both GPIIb/IIIa inhibitors used in patients with
acute coronary syndromes undergoing percutaneous cor-
onary interventions (PCI). A class effect has been as-
sumed for these agents, although they differ in molecular
structure and duration of action. We identified all pla-
cebo-controlled trials of each drug in PCI patients, and
meta-analysed the odds ratios (OR) for death or MI
(D/MI) at 30 days for each set of studies. These ORs were
then compared using a general linear model. RESULTS:
For D/MI at 30 days, the results of the meta-analysis of
the 6 abciximab studies [OR 5 0.52 (0.43, 0.63)] ap-
peared superior to the results of the 3 tirofiban studies
[OR 5 0.73 (0.55, 0.96)], although the differences did
not reach significance. In the model, a non-significant (p 5
0.10) abciximab advantage was observed. The ratio of
the ORs of tirofiban/placebo and abciximab/placebo
meta-analyses was 1.4, suggesting a higher risk of D/MI
at 30 days for tirofiban relative to abciximab. After com-
pletion of these analyses, the results of a randomized
comparison trial of tirofiban vs. abciximab in PCI pa-
tients were announced (for D/MI at 30days OR 5 1.26,
p 5 0.04). The results demonstrated an advantage for ab-
ciximab, in keeping with our meta-analysis result. The
magnitude of the efficacy difference was similar to that
we had predicted. CONCLUSIONS: This is the first time
an indirect comparison of drugs using meta-analytic tech-
niques has been validated with a contemporaneous RCT.
This method should be used to predict results of direct
comparisons of drugs anytime such a trial is contem-
plated.
CV3
DO SHORT-ACTING OPIATES IN OFF-PUMP 
BYPASS SURGERY REDUCE LENGTH OF STAY 
OR TOTAL HOSPITAL COSTS?
Reddy P1, Feret B2, Kulicki L2, Jordan S2, Donahue S2, Quercia R2
1University of Connecticut, Storrs, CT, USA; 2Hartford Hospital, 
Hartford, CT, USA
OBJECTIVES: The cost of remifentanil, a short-acting
opiate, is approximately 10 times higher than fentanyl, a
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longer-acting opiate. Short-acting opiates, however, have
the potential to reduce time to extubation (TTE) and
may, therefore, decrease length of stay (LOS) and hospi-
tal costs. Remifentanil was added to our institution’s
formulary for use during off-pump bypass surgery. The
objective of this analysis was to compare TTE, LOS
and total hospital costs between patients who received
remifentanil and fentanyl during off-pump bypass sur-
gery. METHODS: The study was prospective and obser-
vational in design. Consecutive patients who underwent
off-pump cardiac bypass surgery and received either
remifentanil or fentanyl from September 1998 to August
1999 were included. Patient charges were converted to
costs using cost-to-charge ratios. The percent of patients
extubated in the operating room (OR), LOS and hospital
costs were compared between the groups. RESULTS:
Baseline demographics, including age, female patients,
co-morbidities and intraoperative variables were similar
between the remifentanil (n 5 39) and fentanyl (n 5 20)
groups. Patients given remifentanil during surgery were
significantly more likely to be extubated in the OR than
patients given fentanyl (64% vs. 15%; p , 0.001). The
mean LOS was similar in both groups (7.3 6 3.1d vs. 8.3 6
2.7d; p 5 0.27). Patients who received remifentanil in-
curred lower ward ($3,973 6 1,719 vs. $4,808 6 1,794;
p 5 0.09), recovery room ($31 6 40 vs. $65 6 33; p 5
0.002) and pulmonary function testing costs ($0 6 0 vs.
$34 6 103; p 5 0.045) than patients who received fenta-
nyl. Anesthesia costs were higher among patients who re-
ceived remifentanil ($476 6 102 vs. $416 6 130; p 5
0.06). Medical and surgical supplies, OR, ICU, cardiac
catheterization, laboratory, respiratory therapy, phar-
macy, radiology and transfusion costs were similar be-
tween the 2 groups (p . 0.05). The total cost was
$15,272 6 5,556 and $15,616 6 4,169 in the remifenta-
nil and fentanyl groups, respectively (p 5 0.81). CON-
CLUSION: Remifentanil, when used in off-pump bypass
surgery, increases the likelihood of extubation in the OR.
However, LOS and total hospital costs remain un-
changed.
CV4
USING UK OBSERVATIONAL DATA TO 
IDENTIFY POSSIBILITIES FOR THE
COST-EFFECTIVE IMPROVEMENT OF THE 
TREATMENT OF ATRIAL FIBRILLATION
Piercy J1, James P2, Baum D3, Kuester L3
1Mapi Values, Macclesfield, UK; 2CHKS Ltd, Alcester, UK; 
3Solvay Pharmaceuticals, Hannover, Germany
BACKGROUND: Atrial Fibrillation (AF) is the most fre-
quent type of arrhythmia. Termination of acute AF is
generally undertaken in a hospital setting. Available
drugs for termination of acute AF have severe side effects
and complicated dose regimens. There is a need for new
drugs with a high conversion rate, favourable safety pro-
file and easier dosing. OBJECTIVES: To describe the
characteristics and hospital treatment patterns of patients
with AF. To investigate the requirements for an improved
cost-effective anti-arrhythmic therapy. METHODS: A
database was used containing aggregated and anonymised
diagnostic information, hospital experience (e.g., length
of stay), and demographic data for over 80 million inpa-
tient episodes in the UK over ten years. The database
contains 28,524 hospital admissions of patients (65 and
over) with a diagnosis of AF during 1999/2000. 53.3%
are female, with mean length of stay (LOS) 6.1 days;
46.7% are male with LOS 4.3 days. Controlling for age,
the gender LOS difference is significant (p , 0.01). RE-
SULTS: Comorbid Conditions. 17.5% of AF patients
also had a diagnosis of chronic ischaemic heart disease
(IHD), a further 7.5% had myocardial ischaemia, and
19.5%, congestive heart failure. Furthermore, 24.2% of
CHF patients and 16.9% of all angina patients also had
clinically significant AF. Cardioversion. Cardioversion
(defibrillation) is used when pharmacological therapy
fails to terminate acute AF. However, significant num-
bers (35%) of cardioversion procedures were undertaken
on an elective day case basis. We are currently investigat-
ing and will report on the resource consequences in acute
AF. CONCLUSIONS: There is a clear unmet medical
need for improved anti-arrhythmic drugs. Using the
dataset, we identify two potentially cost-effective possi-
bilities for improved anti-arrhythmic treatment: an agent
which can simultaneously demonstrate effectiveness in
associated cardiovascular conditions such as IHD or
CHF; or an agent reducing the need for cardioversion in
acute AF.
CV5
THE COST-EFFECTIVENESS OF LIFETIME 
FACTOR VIII PROPHYLAXIS IN THE 
TREATMENT OF SEVERE HEMOPHILIA A
Charles RA1, Hay J2
1University of Southern California, School of Pharmacy, Los 
Angeles, CA, USA; 2University of Southern California, Los 
Angeles, CA, USA
Prophylactic infusion of factor VIII has been shown to
markedly reduce arthropathy in patients with severe he-
mophilia A. OBJECTIVE: The purpose of this model is
to investigate the cost-effectiveness of prophylactic infu-
sion of factor VIII relative to on-demand infusion therapy
in patients with severe hemophilia A. METHODS: Two
hypothetical cohorts were modeled; one cohort receiving
prophylactic and the other on-demand infusions. Factor
VIII infusion therapy begins at age 1 and continues un-
changed over a patient’s lifetime. A recursive Markov
model is used to estimate the expected costs and QALYs
associated with each cohort. Costs and QALYs are calcu-
lated using backward induction in 5-year intervals incor-
porating the DEALE method. Data inputs are estimated
from published literature. The analysis is completed from
a societal perspective, uses a 3% discount rate, with costs
in year 2000 U.S. dollars, and has a time horizon of 50
years. RESULTS: According to the model, patients re-
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ceiving prophylactic therapy experience both higher life-
time costs ($3,542,357) and higher QALYs (18.95) than
patients receiving on-demand therapy ($2,455,268, 15.31).
The ICER was determined to be $298,531/QALY. In the
sensitivity analysis, the ICER was sensitive to the number
of units/kg/yr of factor used per patient, the probability
of arthropathy in years 1 through 5, and the utilities as-
signed. Varying these parameter estimates resulted in an
ICER ranging from $8,315 to $616,158/QALY. CON-
CLUSION: Results from the baseline model indicate that
lifetime prophylactic infusion of factor VIII in patients
with hemophilia is above the generally accepted thresh-
old for cost-effectiveness of $50,000 per QALY. Due to
the model’s sensitivity to the amount of factor used, it is
recommended that pharmacokinetic dosing be explored
to reduce the amount of factor needed to achieve thera-
peutic levels. Research to determine more accurate utili-
ties for persons with hemophilia with and without arth-
ropathy are also needed.
CV6
ECONOMIC EVALUATION OF DALTEPARIN, 
ENOXAPARIN AND UNFRACTIONATED 
HEPARIN IN THE TREATMENT OF DEEP VEIN 
THROMBOSIS
Risebrough NA, Mittmann N
HOPE Research Centre, Toronto, ON, Canada
OBJECTIVES: As low molecular weight heparins
(LMWH)s such as enoxaparin (ENOX) and dalteparin
(DALT) add drug acquisition cost, yet eliminate the need
for activated prothrombin time (aPPT) monitoring com-
pared to unfractionated heparin (UFH), we developed an
economic model to quantify the value of DALT, or
ENOX compared to UFH as cost per clinical event
avoided from an health management organization per-
spective. METHODS: With a hypothetical patient cohort
with confirmed DVT, treatment and clinical outcomes
were modeled using a conventional decision tree over a 6
month timeframe. Treatment with LMWH or UFH con-
tinued for an average of 5 days. Possible clinical events
included thrombocytopenia, major bleed, recurrent VTE,
or death from any cause. Inpatient treatment with UFH
was necessary due to the IV route of administration and
need for apt monitoring. Subcutaneous administration of
LMWHs facilitate early discharge from hospital or treat-
ment in the outpatient setting for the duration. Based on
published sources, we assumed the proportion of patients
receiving LMWH as inpatients, outpatients or with early
discharge were 45%, 30% and 25%, respectively. Drug
efficacy was obtained from a meta-analysis of published
clinical trials. Resource use data associated with drugs
and inpatient and outpatient medical care were obtained
from published sources, treatment guidelines and an ex-
pert physician panel. Medical unit costs (2000 $US) were
obtained from published sources. RESULTS: The base-
line analysis showed DALT and ENOX prevented 28 and
17 clinical events respectively per 1000 patients com-
pared to UFH. The total medical cost per patient treated
with DALT, ENOX and UFH was $3199, $3347, and
$5104, (US$) respectively. Compared to UFH, cost sav-
ings with use of LMWH was attributed to reduced clini-
cal events and fewer hospital days. Sensitivity analysis
showed results were robust. CONCLUSIONS: These fig-
ures indicate that LMWHs provide important improve-
ments with medical cost savings and thus are attractive
both clinically and economically.
CV7
COST-EFFECTIVENESS OF CARDIOVASCULAR 
DISEASE (CVD) PREVENTION BY REDUCING 
POSTPRANDIAL HYPERGLYCEMIA
Glick H1, Qiao Q2, Grueger J3
1University of Pennsylvania, Philadelphia, PA, USA; 2National 
Public Health Institute, Helsinki, Finland; 3Novartis 
Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: To estimate the cost-effectiveness of the
insulinotropic agent nateglinide vs. metformin using an
epidemiologic risk model that quantifies the relationship
between glucose spikes as measured by 2 hour postpran-
dial blood glucose (2h-BG) and risks for all cause mortal-
ity, acute myocardial infarction (AMI), and stroke in dia-
betic patients. METHODS: We used data from the
DECODE study database (N 5 22,474, with up 25 years
of follow-up) to estimate parametric failure time models
predicting the risk for death, AMI, and stroke for 2h-BG,
and other CVD risk factors. The risk equations were used
to develop a decision model that projected risks, costs,
and years of life for up to 40 years for men and women
with and without an intervention specifically to control
2h-BG (results for men with 2h-BG .11 mmol/L re-
ported below). Costs included the intervention and the
costs of CVD events. All costs are expressed in Swiss
francs (CHF), and were discounted at 3%. Clinical effi-
cacy was taken from a randomised clinical trial of nateg-
linide versus metformin. RESULTS: When results were
projected for 15, 25, and 40 years, incremental costs
were 9,137, 10,047, 10,133 CHF, respectively (1 CHF z
$0.60). Discounted years of life saved for these same in-
tervals were 0.15, 0.24, and 0.26. The ratios of cost per
year of life saved were 59,600, 41,500, 38,400 CHF.
CONCLUSIONS: Initial modeling suggests that therapy
with nateglinide among individuals with elevated levels
of 2h-BG reduces the risk for death and CVD events and
has acceptable cost-effectiveness ratios compared to met-
formin.
CV8
WORK-RELATED OUTCOMES OF PATIENTS SIX 
MONTHS AFTER MYOCARDIAL INFARCTION
Erickson SR1, McBurney CR1,2, Kline-Rogers EM1, Cooper JV1, 
Mani OCM1, Eagle KA1
1University of Michigan, Ann Arbor, MI, USA; 2Pfizer Inc.,
Ann Arbor, MI, USA
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OBJECTIVES: To determine the rate of return to work
post-MI; and for returnees, self-reported work perfor-
mance and number of days absent. METHODS: Patients
admitted to the University of Michigan Medical Center
with diagnosis of MI were identified consecutively and
prospectively from October 1999 to May 2000. Clinical
data were obtained retrospectively from medical records.
Six months after discharge, patients were interviewed by
telephone to determine work status prior to and after MI.
Work-related outcomes included self-reported work per-
formance using the Work Performance Scale (WP, 1 5
lowest, 4 5 highest performance) and number of days ab-
sent. The SF-12 was administered to determine physical
(PCS-12) and mental (MCS-12) functional status. RE-
SULTS: Of 202 patients interviewed, 30.2% worked
prior to the reference MI. Of these, 80.3% were male,
mean age was 56.1 years, and 26.2% did not return to
work. Those not returning had lower median PCS-12
scores (28.5 versus 42.8 for returnees, p , 0.001), prior
MI (62.5% versus 17.8% for returnees, p 5 0.003), and
history of congestive heart failure (25.0% versus 4.4%
for returnees, p 5 0.03). Returnees had a median WP of
3.6, and 82.2% indicated no absences. Median WP
scores were lower for patients with lower ejection frac-
tions (EF) (3.2 for EF , 40% versus 3.8 for EF3 . 40%,
p 5 0.01), hypertension (3.5 versus 3.8 without hyper-
tension, p 5 0.02), or prior MI (3.3 versus 3.8 without
previous MI, p 5 0.01). Workers reporting absences had
lower EF (40% EF , 40% versus 11.4% EF , 40% for
no absences, p 5 0.05), lower median PCS-12 score (31.1
versus 44.5 for no absences, p 5 0.02), and prior MI
(50.0% versus 10.8% if no absences, p 5 0.02). CON-
CLUSIONS: Preexisting cardiac disease, lower EF at dis-
charge, and poorer physical functioning were negatively
related to work-related outcomes. This small study dem-
onstrates the need for a larger, broader study that in-
cludes, health beliefs, psychosocial assessment, treatment,




THE RELATIONSHIP OF DIABETES SYMPTOMS 
AND HEALTH-RELATED QUALITY OF LIFE
Pfalzgraf AR, Nau DP
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To determine the relationship between di-
abetes symptom burden and patients’ perceptions of
health-related quality of life (HRQL). METHODS: A
questionnaire was sent to 3,716 adults with diabetes en-
rolled in a managed care organization in West Virginia
and southeastern Ohio. Diabetes symptom burden was
measured using a 17-item scale (Diabetes TyPE, Form
2.1). The Health Status Questionaire (HSQ-12), Version
3.0 was utilized to measure patients’ perception of their
HRQL. Analyses focused on six domains from the HSQ-
12: General Health Perception (GHP), Physical Function-
ing (PF), Bodily Pain (BP), Energy/Fatigue (EF), Social
Functioning (SF), and Mental Health (MH). Linear re-
gression was used to examine the impact of diabetes
symptoms on each of the HRQL domains. RESULTS:
Usable responses were obtained from 1,027 persons with
diabetes (27.6% response rate). The summated scale of
diabetes symptom burden had acceptable internal consis-
tency (alpha 5 0.90). Analyses revealed a significant in-
verse relationship between diabetes symptom burden and
each of the six domains from the HSQ-12, when control-
ling for gender, age, and education. Overall symptom
burden was found to be most highly associated with So-
cial Functioning (r 5 2.57), while somewhat less
strongly associated with the other five domains: GHP
(r 5 2.52); PF (r 5 2.49); BP (r 5 2.51); EF (r 5 2.54);
MH (r 5 2.50). As overall symptom burden increases,
the patients’ perception of health across all six HRQL
domains decreases. CONCLUSIONS: Diabetes symptom
burden is inversely related to health-related quality of
life. Thus, interventions targeted towards the alleviation
of diabetes symptoms should also lead to improvements
in patients’ perceptions of their health and well-being.
DG2
THE INCREMENTAL COST OF DIABETES IN 
CHRONIC ILLNESS CO-OCCURRENCES
Garis RI1, Farmer KC2, Arora M1
1Creighton University, Omaha, NE, USA; 2University of 
Oklahoma, Oklahoma City, OK, USA
OBJECTIVES: The cost and management of patients
with multiple chronic conditions present unique chal-
lenges to the health care system. Major chronic condi-
tions such as diabetes often co-occur with other chronic
illnesses. The objective of this study is to report the incre-
mental cost of diabetes mellitus when it co-occurs with
cardiovascular conditions, depression, hypertension, psy-
chosis, respiratory/asthma, or acid peptic disease. METH-
ODS: A one-year retrospective database analysis using an
integrated Medicaid dataset from the State of Oklahoma.
Disease states were identified by ICD-9-CM codes and a
validated drug-based classification. Patients included in
the study had the chronic condition identified by both
drug and diagnosis information. The incremental costs of
diabetes when co-occurring with other chronic condi-
tions was determined by subtracting the cost of the non-
diabetes single condition from the co-occurring disease
group. RESULTS: Seven groups of patients consisted of;
diabetes only (n 5 1038), diabetes co-occurring with hy-
pertension (n 5 313), respiratory illness/asthma (n 5 62),
depression (n 5 48), cardiovascular illness (n 5 35), psy-
chosis (n 5 35), and acid peptic disease (n 5 30). Diabe-
tes as a single chronic illness had an annual cost of $818
over patients with no evidence of chronic illness. The in-
cremental cost of diabetes when co-occurring with psy-
chosis was $7,211, respiratory illness/asthma $3,161, hy-
pertension $1,595, depression $1,319, acid peptic disease
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$977, and cardiovascular illness $235. The incremental
cost of diabetes co-occurring with psychosis was signifi-
cantly higher than all other disease co-occurrences. Dif-
ferences in the incremental cost of diabetes were not sta-
tistically significant between the other disease combinations.
ANCOVA was performed with longevity in the program
as a covariate to adjust for differential enrollment time.
CONCLUSION: The cost and management of chronic
conditions such as diabetes may be highly influenced by
other chronic conditions the patient may have. Disease
management programs may incorporate co-morbidity re-
search and models when evaluating the cost and treat-
ment of chronic conditions.
DG3
A RETROSPECTIVE EVALUATION OF 
NONSTEROIDAL ANTI-INFLAMMATORY
DRUG-INDUCED GASTROINTESTINAL 
COMPLICATIONS AMONG ADULTS IN A 
MANAGED CARE HEALTH PLAN
Dodd MA1, D’Angio R2, Gupchup GV1, Nelson C3
1The University of New Mexico, Albuquerque, NM, USA; 
2Pfizer Inc, Cedar Crest, NM, USA; 3Presbyterian Healthcare 
Services, Albuquerque, NM, USA
OBJECTIVE: To obtain a profile of adult patients at risk
for nonsteroidal anti-inflammatory drug (NSAID) in-
duced gastrointestinal (GI) complications in a large man-
aged care health plan in the Southwest United States.
METHODS: Patients with NSAID prescription claims
between July 1996 and June 1997 were identified from a
health plan claims database. Patients with claims associ-
ated with ICD-9 and CPT codes indicating serious GI
complications were then identified. The ICD-9 codes
used were those associated with GI ulcers (531.x, 532.x,
533.x, and 534). A total of 19 CPT codes for GI proce-
dures indicative of a GI complication were used. A for-
ward stepwise logistic regression analysis, using the likeli-
hood-ratio (LR) test, was performed to identify predictors
of GI complications. Predictors included in the model
were individual NSAIDs and the following potential risk
factors: age, gender, previous GI drug usage, previous
steroid usage, and total days supply of NSAIDs during
the study period. RESULTS: A sample of 15,772 patients
with prescription claims for NSAIDs was identified. Of
these patients, 213 (1.4%) had an ICD-9 or CPT code
suggestive of serious GI complications secondary to a
NSAID. The logistic regression results indicated that
women (OR 5 0.65, 95% CI 5 0.48–0.87) were less
likely to develop GI complications. However, patients
with previous GI drug usage (OR 5 5.97, 95% CI 5
4.51–7.90), those who used ketorolac (OR 5 2.01, 95%
CI 5 1.10–3.67) and those who used oxaprozin (OR 5
1.82, 95% CI 5 1.10–3.00) were more likely to develop
GI complications. CONCLUSION: Users of ketorolac
and oxaprozin, as well as those with previous GI drug us-
age were at a higher risk, while women were at a lower
risk of GI complications in this managed care population.
DG4
DISEASE SEVERITY DETERMINES COST OF 
GASTROESOPHAGEAL REFLUX DISEASE IN A 
MIDWEST USA HEALTH CARE PLAN
Brelje T1, Heaton A1, Martin S1, Bhattacharjya A2, Dodd S2, 
Thornhill J2
1Prime Therapeutics, Inc, Eagan, MN, USA; 2Janssen 
Pharmaceutica Products, Titusville, NJ, USA
OBJECTIVES: The primary objective was to describe the
cost of illness of gastroesophageal reflux disease (GERD)
in a managed care population. Secondary objectives were
to characterize GERD costs and to quantify the depen-
dence of costs on disease severity. METHODS: This ret-
rospective study utilized claims data from a large (1.4
million lives) Midwest USA health care plan. Study popu-
lation had complete medical and pharmacy coverage con-
tinuously from 1996 to 1998 and possessed at least one
medical claim for GERD. Claim costs were compiled for
all GERD-attributable medical and drug claims. Costs
were also categorized by health care sector, such as hos-
pital inpatient or pharmacy. ICD-9 codes were used to
categorize subjects’ GERD into four progressively worse
states plus a non-symptomatic state: GERD0 {no GERD
claims}, GERD1 {mild esophagitis}, GERD2 {reflux esoph-
agitis}, GERD3 {esophageal ulceration}, and GERD4 {stric-
tures and complications}. RESULTS: A total of 7575 sub-
jects meeting the inclusion and exclusion criteria were
identified. The median age was 50 and there were 50%
females. Over the three year study period, more than $23
million was spent on GERD-related claims, or $86 per
subject per month. Pharmacotherapy contributed 31% of
GERD health care costs, inpatient hospital charges 37%,
outpatient facility charges 26%, and doctor office charges
6%. Mean cost per month was highly dependent on GERD
disease state: GERD0 cost $38 per month, GERD1 was
$189, GERD2 was $232, GERD3 was $536, and GERD4
was $412. At higher GERD states, pharmacotherapy was
a lower contributor to cost. CONCLUSIONS: For payers
of health care, GERD is an expensive disorder to manage.
Overall costs associated with GERD increase with the se-
verity of the disease, although the relative contribution of
each health care cost sector changes with disease severity.
INFECTIOUS DISEASE
ID1
DEVELOPMENT OF A STOCHASTIC DECISION 
ANALYSIS MODEL OF TREATMENT OF 
PYELONEPHRITIS FROM THE RESULTS OF
AN RCT
Davey P1, Wang J1, Claxton K2, Fenwick E2, Sculpher M2, 
Talan D3
1University of Dundee, Dundee, Scotland; 2University of York, 
York, UK; 3Olive View-UCLA Medical Centre, Sylar, CA, USA
OBJECTIVE: To model the relationship between resis-
tance to trimethoprim sulphamethoxazole (TMP-SXT)
60 Abstracts
and outcome of pyelonephritis from an RCT comparing
TMP-SXT with ciprofloxacin (Talan, JAMA, 283:1583–
1590,2000). METHODS: In the trial cost analysis was
limited to a comparison between the two treatment
groups, which did not permit analysis of effect modifiers,
such as TMP-SXT resistance. A probabilistic model was
developed and distributions were assigned to expected
costs and probabilities of cure, failure (persistent or re-
current infection) and superinfection (reinfection with a
new organism) from the trial data. These distributions,
which characterise the second order uncertainty sur-
rounding these outcomes following the trial, were propa-
gated through the model using Monte Carlo simulation
in order to generate cost-effectiveness acceptability curves.
RESULTS: There were 255 patients in the per protocol
analysis. The mean cost for patients with treatment fail-
ure ($476, n 5 34) was significantly higher than the cost
for patients who were either cured ($307, n 5 174) or
had superinfection ($325, n 5 11). However, treatment
with ciprofloxacin reduced both the probability and cost
of treatment failure (the mean difference in treatment
cost between success and failure was only $4 in the cipro-
floxacin arm compared with $267 in the TMP-SXT arm).
The probability that ciprofloxacin was dominant (greater
efficacy at lower cost) was .95% at 18% TMP-SXT re-
sistance and remained .95% down to a resistance rate of
10%. These results were sensitive to a small number of
hospitalisations (1 ciprofloxacin, 5 TMP-SXT). Taking
outpatient costs alone, the threshold value of treatment
failure at which ciprofloxacin was 90% likely to be cost-
effective ranged from $700 for 18% resistance to $350
for 30% resistance. CONCLUSIONS: The stochastic model
produces results that are importantly different from a
simple analysis based on point estimates of probability
and cost, particularly if the latter assumes that the cost of
treatment failure is the same for both treatments.
ID2
HEALTH VALUES FOR THE LIPODYSTROPHY 
SYNDROME
Lenert LA1, Fedderson M2, Sturley A2, Lee D1
1University of California at San Diego, San Diego, CA, USA; 
2San Diego VA Research Foundation, San Diego, CA, USA
BACKGROUND: There is increasing concern about the
potential effects of the lipodystrophy syndrome on the health
and quality of life of HIV-infected patients. OBJECTIVE:
Understand patients’ perception of the significance of the
lipodystrophy syndrome’s quality-of-life effects. DESIGN:
Cross-sectional study of volunteer HIV-infected patients.
SETTING: An urban, university-affiliated HIV clinic in
San Diego, California. Patients: 75 well-educated, predom-
inantly male, HIV-infected patients. MEASUREMENTS:
Patients’ beliefs about the importance of appearance upon
quality of life and preferences for hypothetical states per-
formed using the standard gamble and time trade-off
methods. RESULTS: Almost all patients (95%) indicated
that appearance was important to their quality of life,
and 89% agreed that they would be “really bothered” if
their HIV diagnosis were revealed by their appearance.
Patients were willing, on average, to give up 2 years (s.d.
2.8), out of a 10-year life-expectancy, to live in good
health rather than live with the syndrome, over and
above what they would give up to be free of symptoms
from HIV infection. Patients would take an additional
13% (s.d. 20%) risk of death to be cured of HIV infec-
tion when complicated by the syndrome (median increase
in risk, 9%), above the risk they would accept to be cured
of uncomplicated HIV infection. The amount that the pa-
tients would trade off was associated with beliefs about
the importance of their appearance to quality of life (p 5
0.0045) and worry that their appearance would expose
their diagnosis by (p 5 0.032). CONCLUSIONS: The
physical effects of the lipodystrophy syndrome are impor-
tant enough to cause many patients to consider accepting
considerable risks of death or trading off substantial life-
expectancy to avoid the syndrome. Physicians may need
to tailor HIV care to this aspect of patients’ preferences.
ID3
COST-EFFECTIVENESS ANALYSIS OF AN 
INTRANASAL INFLUENZA VACCINE FOR 
HEALTHY CHILDREN
Luce B1, Zangwill K2, Palmer C1, Mendelman P3, Yan L4,
Wolff M4, Cho I3, Iacuzio D5, Belshe B6
1MEDTAP International Inc, Bethesda, MD, USA; 2Harbor-
UCLA Medical Center, Torrance, CA, USA; 3Aviron, Mountain 
View, CA, USA; 4The EMMES Corporation, Potomac, MD, 
USA; 5Roche Pharmaceuticals, Nutley, NJ, USA; 6St. Louis 
University, St. Louis, MO, USA
OBJECTIVE: Intranasal influenza vaccine has proven
clinical efficacy and may be better tolerated by young
children and their families than an injectable vaccine.
This study determined the potential cost-effectiveness
(CE) of intranasal influenza vaccine among healthy chil-
dren. METHODS: The CE analysis included clinical and
medical utilization data collected in 1996–8 during a pro-
spective 2-year efficacy trial of intranasal influenza vac-
cine. These data were supplemented with data from the
literature where necessary. The analysis included both di-
rect and indirect costs. The trial enrolled 1,602 healthy
children 15–71 months of age in year 1, 1,358 of whom
were enrolled in year 2. Children received 1 or 2 doses of
either intranasal influenza vaccine or placebo. The main
outcome measure was cost per febrile influenza-like ill-
ness (ILI) day avoided. The base case assumed that the
vaccine was given twice in the first year and once each
year thereafter at a total cost of $20 for the vaccine and
its administration (i.e. per dose). RESULTS: Vaccinated
children had an average of 1.2 fewer ILI fever days over 2
years than unvaccinated children. In an individual-based
vaccine delivery scenario, CE was approximately $30/
febrile ILI day avoided with the vaccine, and ranged from
$10–$59/febrile ILI day avoided at a cost per dose of
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$10–$35, respectively. In a group-based delivery sce-
nario, vaccination was cost-saving compared to no vac-
cine and remained so if the vaccine cost was ,$28/dose
(the break-even price). In the individual-based scenario,
vaccination was cost-saving if the cost was ,$5/dose. In
this scenario, nearly half of lost productivity in the vac-
cine group was attributable to visits to administer the
vaccine, which overshadowed the relatively modest sav-
ings in ILI-associated costs averted. CONCLUSIONS:
Routine use of intranasal influenza vaccine among healthy
children may be cost-effective and may be maximized by
using group-based vaccination approaches.
ID4
THE CONFUSION BETWEEN SEPTICEMIA AND 
SEVERE SEPSIS
Linde-Zwirble WT1, Ball DE2, Cooper LM2, Lidicker J1,
Angus DC3
1Health Process Management, Owings Mills, MD, USA; 2Eli Lilly 
and Company, Indianapolis, IN, USA; 3University of Pittsburgh 
School of Medicine, Pittsburgh, PA, USA
INTRODUCTION: The American College of Chest Phy-
sicians/Society of Critical Care Medicine Consensus Con-
ference defined severe sepsis as a systemic inflammatory
syndrome in response to infection associated with acute
organ dysfunction. Often, septicemia codes have been
used in administrative datasets as a proxy for severe sep-
sis. However, these entities are not necessarily the same
and one study found large differences in mortality be-
tween septicemia patients with and without severe sepsis
(54% vs. 15%). We explored the accuracy of septicemia
codes as identifiers of severe sepsis. METHODS: We se-
lected all patients with septicemia or severe sepsis (bacte-
rial or fungal infection plus acute organ failure) in the
1996 Florida hospital discharge database (n 5 1,936,479)
and compared differences between the groups. Septicemia
was defined using the ICD-9-CM code 038.xxx. We de-
fined severe sepsis using a more sophisticated strategy pre-
viously validated against prospective clinical and physio-
logic criteria. RESULTS: We found 58,598 patients with
severe sepsis, 53.4% of whom were in the intensive care
unit (ICU). We found 57,875 patients with septicemia,
30.9% of whom were in the ICU. Patients with severe
sepsis had a higher mortality (24.1% vs. 18.0%, p ,
0.001) and higher hospital costs ($20.4k vs. $14.4k, p ,
0.001). For patients with an ICU stay, hospital mortality
was 14.4% among the 7,927 septicemia cases without se-
vere sepsis, 23.5% among the 21,655 cases of severe sep-
sis without septicemia and 42.1% among the 9,970 cases
of severe sepsis with septicemia. The mean hospital cost in
these three groups was $18,381, $24,396, and $33,470
respectively. Of all selected patients (n 5 99,126), 17.5%
met criteria for both septicemia and severe sepsis. The
sensitivity and positive predictive values of septicemia
codes as predictors of severe sepsis are 29.6% and 30.0%
respectively. CONCLUSIONS: Septicemia codes are not
accurate for identifying patients with severe sepsis.
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THE IMPACT OF SECOND-GENERATION 
ANTIPSYCHOTIC MEDICATIONS ON 
AMBULATORY PATIENTS WITH 
SCHIZOPHRENIA
Mulani PM, McCombs J
University of Southern California, Los Angeles, CA, USA
BACKGROUND: The Medi-Cal program in California
added second-generation antipsychotic medications to its
formulary in October 1997. OBJECTIVE: Investigate the
impact of the formulary expansion on patient outcomes
for olanzapine and risperidone patients before and after
the formulary expansion. STUDY POPULATION: The
study population consisted of 13,106 olanzapine and
15,718 risperidone ambulatory patients from the 100%
Medi-Cal dataset, who were classified into 3 groups.
New: no previous antipsychotic drug therapy history. Re-
starters: re-started antipsychotic drug therapy while not
on active therapy. Switcher: who switched to one of these
products while on active drug therapy. METHODS:
Models of one-year treatment costs were estimated using
both OLS regression and propensity score methods.
Models included over 85 covariates for patient demo-
graphics, prior use of services, prior antipsychotic drug
profile and diagnostic profile. Separate models were esti-
mated for the 3 patient populations. Outcomes include
total costs over one year broken down into component
costs and days of uninterrupted drug therapy achieved af-
ter re-starting therapy. RESULTS: The formulary expan-
sion immediately increased the number of new, switcher,
restarter patients starting therapy with risperidone and
olanzapine. Olanzapine patients were more likely to be
male, between the ages of 30 and 60, urban residents and
AFDC recipients. For restarters and switchers, Olanza-
pine patients also appear to be more compliant with their
prior antipsychotic drug regimen. Once these differences
were accounted for, Risperidone and olanzapine patients
exhibited similar treatment cost profiles in the post-
expansion period. CONCLUSIONS: More research is
needed to determine if the formulary expansion reduced
the cost of treating patients with schizophrenia. Further-
more, future comparison across drugs must take into ac-
count potential treatment selection bias and formulary
expansion effects on the decision to start drug therapy.
MH2
FUTURE EMPLOYABILITY: A NEW APPROACH 
TO COST-EFFECTIVENESS ANALYSIS OF 
ANTIPSYCHOTIC THERAPY
Ganguly R, Miller LS, Martin BC
University of Georgia, Athens, GA, USA
OBJECTIVE: Antipsychotic therapies are often evaluated
on the basis of clinical endpoints (BPRS, PANSS) and
measures of direct cost. However, schizophrenia patients
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pose a substantial burden in terms of indirect costs, much
of which is attributable to loss of employment. We
present a new approach to assess the cost-effectiveness of
Risperidone Vs Haloperidol, using employability as an
outcome measure. METHODS: A decision analytic cost-
effectiveness model was developed to compare the two
treatments over a one-year period including all direct
medical costs and the number of employable persons as a
measure of effectiveness. A measure of executive func-
tioning, the Wisconsin Card Sort Test (WCST), was used
as an intermediate endpoint from which employability
was modeled. A Monte-Carlo procedure, using WCST
sampling distributions from clinical trials, simulated the
WCST score distribution for a cohort of 10,000 patients.
A clinically stable patient, with a Positive and Negative
Syndrome Scale (PANSS) score increase of at least 20%
and a WCST-Category score of >3.5 was assumed to be
employable. Sensitivity analysis was performed for key
values. RESULTS: The base case per-patient cost of Ris-
peridone and Haloperidol was $5,967 and $4,622 re-
spectively and the number of employable persons was
3,258 (32.58%) and 2,517 (25.17%) respectively. Ris-
peridone remained cost increasing and had higher num-
ber of employable persons over all the ranges used in the
sensitivity analysis. The base case incremental cost-effec-
tiveness ratio for Risperidone was $14,507 for each addi-
tional employable person. The incremental CE ratio
ranged from a high of $100,000 to a low of $3,000 per
employable persons when the rates of clinical stability for
Risperidone and Haloperidol therapy were varied. CON-
CLUSION: Gains from earning rates for employed
schizophrenics, savings in informal caregiver costs and
other intangible positive effects could justify an incre-
mental cost of $14,507 for each additional employable
person prescribed Risperidone.
MH3
CLINICAL ASSESSMENT OF QUALITY OF LIFE 
AMONG SCHIZOPHRENIA PATIENTS WITH 
DEFICIT SYNDROME
Russo P1, Kirkpatrick B2
1The MEDSTAT Group Inc, Washington, DC, USA; 2University 
of Maryland Psychiatric Research Center, Baltimore, MD, USA
OBJECTIVE: To determine whether persons with deficit
syndrome exhibit lower quality of life than do their coun-
terparts. METHODS: Participants were drawn from the
U.S. Schizophrenia Care and Assessment Program (SCAP).
Trained assessors collected baseline data. Baseline QLS
was used (n 5 781; mean 5 56) and was modeled as a
linear function of covariates, including demographic,
clinical, medication adherence, and site variables. Pres-
ence of deficit syndrome was assigned based on proxy
methods using clinical data collected at the baseline as-
sessment (Kirkpatrick B., et al., 1993). RESULTS: Mod-
eling revealed that deficit syndrome had a negative im-
pact of 4.7 points (p , .001) on quality of life score
(range 0–120), suggesting that persons with deficit syn-
drome may experience a significantly lower quality of life
than their non-deficit counterparts, all else equal. Those
having higher hallucinations/delusions scores (p , .001)
exhibited lower QLS scores and those with higher func-
tioning scores (GAF; p , .001) exhibited higher QLS
scores. The presence of insurance other than Medicare or
Medicaid (as compared to no insurance) revealed a posi-
tive relationship to QLS score. Significance was achieved
on one site variable and indicated a negative relationship.
Weak evidence was obtained (p 5 .0587) indicating a
positive association between higher education level and
QLS score. CONCLUSIONS: Findings suggest that per-
sons with deficit syndrome experience lower quality of
life than those who are non-deficit. The result is expected
given the use of clinical assessment of quality of life and
is contrary to the expectation of higher self-reported
quality of life for persons with deficit. Although the clini-
cal and functional scores are significant, the impact of
deficit syndrome is at least five times greater than that of
hallucinations/delusions. The interpretation of signifi-
cance on the insurance and site variables is less clear and
may suggest that the observed variation is a result of an
unobserved mediating process, such as selection or differ-
ential access.
MH4
APPLICATION OF THE RASCH MODEL TO THE 
SF36 MENTAL HEALTH 5 ITEM SCALE (MH5)
Perneger TV, Bovier PA
Geneva University Hospital, Geneva, Switzerland
OBJECTIVES: To verify whether the SF36 Mental
Health 5 item scale (MH5), an instrument commonly
used in mental health research, fulfills criteria of unidi-
mensionality and invariant measurement specified by
item response theory (IRT). METHODS: As part of a
survey of health care needs among university students in
Geneva, Switzerland, 1257 respondents (64% of eligible
persons) filled the MH5 (version 2). Each item was
scored on a 5-level frequency scale (“never” to “all of the
time”). We analyzed these data using both the traditional
method (summative scoring), and the polytomous one-
parameter IRT (or Rasch) model. RESULTS: In tradi-
tional analysis, the MH5 scale performed as expected
(single factor, Cronbach alpha 0.85, mean 67.1, standard
deviation 17.6, range 0–100). Rasch analysis revealed the
good fit of all item characteristic curves. Threshold loca-
tions for feeling “nervous” (mental health logits: 23.2,
20.7, 2.0, 3.3), “down in the dumps” (24.0, 21.7, 0.4,
1.5), “calm and peaceful” (23.0, 20.6, 0.9, 6.0), “down-
hearted and blue” (24.2, 21.6, 1.0, 3.0), and “happy”
(23.1, 20.9, 0.7, 4.2) were all ordinal, consistently with
theory, and spread widely over a span of 10.2 logits.
While classic MH5 scores and Rasch-based scores were
closely correlated (r 5 0.98), their relationship was
S-shaped: the intervals, in mental health logits, between
MH5 scores 0–10, 10–20, etc, up to 90–100 were: 2.23,
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1.22, 1.00, 0.90, 0.85, 0.83, 0.90, 1.09, 1.54, and 3.21.
CONCLUSIONS: The five MH5 items fit the Rasch
model very well. Classic summative scoring tends to com-
press the measurement scale at its extremities, by assign-
ing scores that are too low at the high end, and too high
at the low end. Rasch scoring may render MH5 more




COST-EFFECTIVENESS OF INTERVENTIONS 
FOR LATERAL EPICONDYLITIS: RESULTS FROM 
A RANDOMIZED CONTROLLED TRIAL IN 
PRIMARY CARE
Korthals-de Bos IBC, Smidt N, Tulder M, Bouter L
Vrije Universiteit Amsterdam, Amsterdam, Netherlands
OBJECTIVES: In 1997, the Dutch College of General
Practitioners in the Netherlands issued guidelines which
recommend a wait-and-see policy for patients with lateral
epicondylitis. However, these guidelines are not evidence-
based. This paper presents the results of an economic
evaluation in conjunction with a randomized controlled
trial to evaluate the effects of three interventions for pa-
tients with lateral epicondylitis. METHODS: 185 Pa-
tients with pain at the lateral side of the elbow were ran-
domized to one of three interventions: a wait-and-see
policy (n 5 59), corticosteroid injections (n 5 62) or
physiotherapy (n 5 64). Clinical outcomes included gen-
eral improvement, pain during the day, elbow disability
and quality of life (EuroQol). Direct and indirect costs
were measured by means of cost diaries over a period of
12 months. Differences in mean costs between groups
were evaluated by applying non-parametric bootstrap
techniques. RESULTS: After 12 months, the success rate
in the physiotherapy group (91%) was significantly
higher than in the injection group (69%), but only
slightly higher than in the wait-and-see group (83%).
With regard to pain during the day and elbow disability,
physiotherapy differed significantly over time, comparing
to injection group, for these clinical outcomes. The mean
total costs per patient for corticosteroid injections were
Euro 430, compared to Euro 631 for the wait-and-see
policy and Euro 921 for physiotherapy. These differences
were statistically significant for corticosteroid injections
compared to physiotherapy. The cost-effectiveness ratios
showed no statistically significant differences between the
three groups. The cost-utility ratio comparing physio-
therapy and wait-and-see policy was 34,461 (1,982;
9,535,522); the other cost-utility ratios were not statisti-
cally significant. CONCLUSIONS: The results of this
economic evaluation provide no reason to update or
amend the Dutch guidelines for general practitioners,
which recommend a wait-and-see policy for patients with
lateral epicondylitis.
MS2
RESPONSIVENESS TO CHANGE OF THE SF-36 IN 
RAPOLO, A LONGITUDINAL STUDY OF 
RHEUMATOID ARTHRITIS PATIENTS TREATED 
WITH ETANERCEPT
Lubeck DP1, Yelin E1, Katz P1, Roepke L1, Wanke LA2,
Buatti M3
1University of California at San Francisco, San Francisco, CA, 
USA; 2Immunex Corporation, Seattle, WA, USA; 3Wyeth-
Ayerst Research, Philadelphia, PA, USA
OBJECTIVES: To evaluate the responsiveness of the SF-
36 subscales, the generic physical (PCS) and mental
(MCS) components of the SF-36, and the SF-36 Arthritis-
Specific Health Index (ASHI) to changes in disability
measured by the Health Assessment Questionnaire
(HAQ) in RAPOLO. METHODS: We identified 388 par-
ticipants from RAPOLO, a longitudinal, observational
study of RA, who had repeated measures of arthritis spe-
cific function (HAQ and ASHI) and general function (SF-
36). We categorized patients into three groups according
to HAQ score—(1) stable, (2) declined (increase in HAQ
score .of 0.25) and (3) improved (a decline in HAQ
score of .0.25). For each group we calculated Guyatt’s
statistic—a measure of responsiveness to change. The
larger the absolute value of Guyatt’s statistic, the greater
the responsiveness to change. RESULTS: Cohort is 79%
female; mean disease duration is 13.2 yrs; mean age is 55
yrs. There were 286 participants who had no change in
HAQ score. Guyatt’s statistic ranged between 0.04 to
0.17 (Social Functioning). There were 52 participants
who declined. The Guyatt’s statistics for the SF-36
ranged from 0.11 (Role Emotional) to 1.88 (Role-Physi-
cal). There were 46 participants who improved in HAQ
score. The Guyatt’s statistic ranged from 0.14 (Mental
Component Summary Score) to 1.58 (Role-Physical).
CONCLUSIONS: Statistics less than 0.3 indicate no re-
sponsiveness to change, statistics .0.5 reflect responsive-
ness to change. The physical subscales of the SF-36, the
PCS, and the ASHI were moderately to highly responsive
to change in HAQ score. The emotional subscales were
not responsive to change in disability.
MS3
CORRELATION OF A GENERIC HEALTH-
RELATED QUALITY OF LIFE QUESTIONNAIRE 
AND SELF-ADMINISTERED RHEUMATOID 
ARTHRITIS DISEASE ACTIVITY INSTRUMENT
Kim SS, Drabinski AM, Williams GR, Formica CA
Knoll Pharmaceutical Company, Mount Olive, NJ, USA
BACKGROUND: Health-related quality of life (HR-
QOL) measures have been used to study the impact of
disease activity in patients with rheumatoid arthritis
(RA). The objective of this study was to evaluate the cor-
relation between SF-36 scales, physical function (PF), role
physical (RP) and bodily pain (BP) and Rapid Assessment
of Disease Activity in Rheumatology (RADAR). METH-
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ODS: Baseline data was analyzed from the Study of New
Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM), a 5-year
prospective, longitudinal, inception cohort study to docu-
ment long-term functional, clinical, and humanistic out-
comes and patterns of treatment in patients with new
onset rheumatoid arthritis. Baseline data collection con-
sisted of RADAR and SF-36 via telephone interviews by
trained interviewers. To assess the correlation, Pearson
product moment correlation coefficients were calculated.
RESULTS: One hundred thirty-one patients completed
the baseline survey. Mean age of the sample was 56
years; 78% were female; 82% were Caucasian. SF-36’s
PF, RP, and BP scales had means of 54 (SE 5 0.02), 31
(SE 5 0.03), and 47 (SE 5 0.02), respectively. Mean
scores for RADAR items were 7.2 (SE 5 0.22) for “ar-
thritis activity over the past 6 months (AA6M)”, 4.9
(SE 5 0.23) for “arthritis activity today (AAT)”, 4.2 (SE 5
0.22) for “arthritis pain today (APT)”, and 2.6 (SE 5
0.15) for “morning stiffness today (MST)”. SF-36’s PF
scale correlated with AA6M (r 5 0.39, p , 0.001), AAT
(r 5 0.49, p , 0.001), APT (r 5 0.51, p , 0.001), and
MST (r 5 0.40, p , 0.001). SF-36’s RP scale correlated
with AA6M (r 5 0.37, p , 0.001), AAT (r 5 0.38, p ,
0.001), APT (r 5 0.44, p , 0.001), and MST (r 5 0.33,
p , 0.001). SF-36’s BP scale correlated with AA6M (r 5
0.50, p , 0.001), AAT (r 5 0.48, p , 0.001), APT (r 5
0.59, p , 0.001), and MST (r 5 0.42, p , 0.001). CON-
CLUSION: The SF-36’s BP domain resulted in the high-
est correlation with RADAR items. The APT item of
RADAR had the highest correlation with all three do-
mains of SF-36. These results suggest that the level of
bodily pain is indicative of functioning and well-being of
patients.
MS4
A SYSTEMATIC REVIEW OF HEALTH STATE 
VALUES FOR OSTEOPOROSIS RELATED 
CONDITIONS
Brazier JE1, Green C2, Kanis J1
1University of Sheffield, Sheffield, UK; 2MEDTAP UK, London, UK
An important weakness of economic models in the field
of osteoporosis has been the dependence on assumptions
or expert judgments rather than empirical estimates for
the utility values of key health events associated with os-
teoporosis. OBJECTIVES: This paper seeks to identify
the best available utility estimates for health states associ-
ated with osteoporosis and make recommendations about
their use. METHODS: This review has been based on a
systematic search of the main literature databases. Stud-
ies meeting the inclusion criteria have been reviewed in
terms of the appropriateness of the valuation technique,
the validity of the descriptive system (where one was
used), the number and type of respondents and overall
study quality. RESULTS: Twenty-three estimates of health
state values (HSVs) were found across four conditions
from five studies. These empirical estimates were found
to differ significantly from the commonly used assump-
tions in published economic models of interventions or
osteoporosis, but with a wide variation between esti-
mates for the same state (0.32 to 0.80) for vertebral frac-
ture states). This variation can be partly explained by
differences in the valuation technique, health state de-
scriptions and the background and perspective of the re-
spondent, and leaves considerable scope for discretion
that could be abused. There are also problems in apply-
ing values obtained from these studies to the populations
being examined in economic models and a particular dif-
ficulty in predicting the HSV in those who avoid a frac-
ture as a result of an intervention. CONCLUSION: The
review recommends a set of HSVs as part of a reference
case for use in economic models. Due to the paucity of
good quality estimates in this area, further recommenda-
tions are made regarding the design of future studies to
collect HSVs relevant to economic models.
RESPIRATORY DISORDERS/DISEASES
RS1
OUTCOME ASSESSMENT IN PEDIATRIC 
ASTHMA: A COMPARISON OF SYMPTOM-FREE 
TIME AND MULTI-ATTRIBUTE SCALE
Chiou CF1, Weaver MR2, Bell MA2
1Zynx Health Inc.—a subsidiary of Cedars-Sinai Health System, 
Beverly Hills, CA, USA; 2University of Washington, Seattle, 
WA, USA
INTRODUCTION: Most current asthma outcome mea-
sures are either not sensitive enough to detect changes
caused by interventions or not broad enough to cover all
health domains affected by the disease. OBJECTIVE: To
develop a comprehensive measure of health outcomes for
children with asthma that is in compliance with the rec-
ommendations of the U.S. Panel on Cost-Effectiveness in
Health and Medicine, and compare health outcomes esti-
mated with that measure to those estimated with the
symptom-free day, the most commonly used measure.
METHODS: 1) Develop a multi-attribute Pediatric
Asthma Health Outcome Measure, PAHOM, that as-
sesses the impact of asthma on children’s symptoms,
emotions, and physical activity; 2) Collect data on prefer-
ence weights (Ui) for asthma health states from 101
adults using the standard gamble technique; 3) Collect
data on the incidence of health states (Pi) from 72 chil-
dren with asthma using PAHOM calendar; and 4) Calcu-
late the expected utility by summing all of (Ui*Pi). The
expected utility can be used as a proxy of health outcome
if it is assumed that health outcomes of these children are
constant for the remaining life years. RESULTS: On a
scale ranging from zero to one, where perfect health had
a score of one, the average utility of pediatric asthma pa-
tients in the study was 0.900 when measured with the
PAHOM, compared to 0.955 when measured with a
symptom-free day. CONCLUSION: PAHOM, a more
comprehensive measure of health outcomes than symp-
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tom-free day measure, provides lower estimates of aver-
age utility of asthma pediatric asthma patients.
RS2
USING SELF-ADMINISTERED DIRECT TTO 
QUESTIONS TO ELICIT UTILITY VALUES FOR 
ASTHMATIC PATIENTS WITH DIFFERENT 
SEVERITY OF DISEASE
Szende A1, Meszaros A2, Berta GY3, Stahl E4, Svensson K4
1AstraZeneca, Torokbalint, Hungary; 2Semmelweis Medical 
University, Budapest, Hungary; 3Hospital for Chest Diseases, 
Mosdos, Hungary; 4AstraZeneca R&D Lund, Lund, Sweden
OBJECTIVES: To gain utility values for asthmatic pa-
tients, self-administered direct TTO questions may seem
to be a simple option. This study examined reported
TTO values by disease severity groups, and the relation-
ship between other health status measures, and with age.
METHODS: 228 consecutive adult outpatients and inpa-
tients at four sites in Hungary participated in the study.
Doctors had to report GINA severity group and lung
function values. Patients had to fill in three QoL ques-
tionnaires and a direct TTO question that offered a
choice between 20 years in current health or shorter
length of life in perfect health. Statistical analysis applied
F-statistics. RESULTS: Mean TTO values were 0.99,
0.96, 0.82, 0.73 in the four severity groups, respectively.
These were higher than corresponding EQ-5Dindex re-
sults of 0.93, 0.76, 0.65, 0.52. Correlation coefficients
between TTO values and EQ-5Dindex, EQ-5Dvas, SF-
36(PCS), SF-36(MCS), SGRQ, and FEV1% were 0.40,
0.40, 0.34, 0.25, 20.36, and 0.36, respectively. Age ex-
plained 23% of differences in TTO values after control-
ling for asthma severity. Within severity groups 4 and 3,
patients over 50 reported TTO values lower by 0.21 and
0.20 than those below this age. These differences were
larger than corresponding differences in EQ-5D index
values suggesting that direct TTO responses may incor-
porate different concepts of remaining life years of the
older. Results were statistically significant (p , 0.0001).
CONCLUSIONS: Utility values gained from direct TTO
questions can lead to higher scores than generic utility-
based questionnaires, low correlation values with other
measures, and to biases in patient groups of heteroge-
neous age.
RS3
PSYCHOMETRIC EVALUATION OF THE CAP-
SYM QUESTIONNAIRE: A NEW, PATIENT-BASED 
MEASURE OF SYMPTOMS IN COMMUNITY 
ACQUIRED PNEUMONIA
Lamping D1, Schroter S1, Sagnier PP2, Duprat-Lomon I2
1London School of Hygiene & Tropical Medicine, London, UK; 
2Bayer Plc, Slough, UK
OBJECTIVES: To develop a practical and scientifically
rigorous, patient-based outcome questionnaire to evalu-
ate symptoms in community-acquired pneumonia (CAP).
METHODS: The CAP-Symptom questionnaire (CAP-
Sym) is an 18-item, interviewer-administered question-
naire that measures the bothersomeness of 18 symptoms
during the past 24 hours using a 6-point Likert scale. We
used gold-standard psychometric methods to comprehen-
sively evaluate the acceptability, reliability, validity and
responsiveness of the CAP-Sym in field testing involving
556 patients in 13 countries. The development and vali-
dation of the CAP-Sym were carried out as part of the
CAP 2000 study, a multicentre, multinational, prospec-
tive, randomised, double-blind study to compare the ef-
fectiveness of moxifloxacin oral tablets to standard oral
treatment regimes in patients with CAP. RESULTS: Field
testing in all countries confirmed the acceptability (item
non-response, item endorsement frequencies, item/scale
floor and ceiling effects), reliability (internal consistency,
item-total and inter-item correlations, test-retest reliabil-
ity), validity (content, construct, convergent, discrimi-
nant, known groups) and responsiveness of the CAP-
Sym. CONCLUSIONS: The CAP-Sym is a practical and
scientifically sound patient-based outcome measure that
can be used to evaluate CAP-related symptoms in clinical
trials or clinical audit. The disease-specific CAP-Sym
shows preliminary evidence of being more responsive
than the generic SF-36 as a measure of outcome in CAP.
RS4
A MODEL-BASED EVALUATION OF INHALED 
STEROIDS IN MILD-TO-MODERATE ASTHMA
Paltiel A1, Fuhlbrigge A2, Kitch B2, Weiss S2, Neumann P3, 
Kuntz K3
1Yale School of Medicine, New Haven, CT, USA; 2Harvard 
School of Medicine, Boston, MA, USA; 3Harvard School of 
Public Health, Boston, MA, USA
OBJECTIVE: To forecast the discounted costs and clini-
cal consequences of inhaled corticosteroids (ICS) in a
population of adults with mild-to-moderate asthma.
METHODS: We developed a Markov, state-transition
simulation of asthma patient care and its pharmacoeco-
nomic impact. We employed this framework to compare
quick relievers (e.g., b-agonists) on an as-needed basis to
quick relievers plus ICS therapy targeted to one of three
severity sub-populations. State-space dimensions included
patient age, clinical history, and lung dysfunction (mea-
sured via forced expiratory volume in one second, FEV1).
Risk functions were estimated from symptom, exacerba-
tion, and hospitalization rates obtained from literature
reviews and analyses of primary, cross-sectional data. Sys-
tematic review of published trials yielded 16 eligible stud-
ies and produced the following outcome ranges for sensi-
tivity analysis: 1%–21% improvement in FEV1; monthly
costs of $14–$76; and 0%–4% probability of major tox-
icity. Societal costs were derived from published economic
studies of inpatient and outpatient asthma. We collected
preference weights (using standard gambles, time trade-
offs, and the Health Utilities Index) in a cross-sectional
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study of 100 adult asthmatics. RESULTS: The table re-
ports outcomes over a 10-year period. Results were driven
by the impact of ICS on quality of life, rather than on
mortality. Findings were stable over most input data
ranges. However, at efficacy levels below 3% and toxic-
ity rates greater than 2.9%, the cost-effectiveness esti-
mate exceeded $100,000/QALY. CONCLUSION: Results
suggest that inhaled steroids deliver good comparative
value in mild-to-moderate adult asthma. More research is







JOINT COUNTS IN PATIENTS WITH NEW 
ONSET RHEUMATOID ARTHRITIS: PATIENT VS. 
PHYSICIAN ASSESSMENT
Kim SS, Drabinski AM, Williams GR, Formica CA
Knoll Pharmaceutical Company, Mount Olive, NJ, USA
BACKGROUND: Both physician-assessed and patient
self-reported joint counts have been used in the assess-
ment of disease activity in rheumatoid arthritis. The ob-
jective of this study was to compare patient vs. physician
reported joint counts in patients with new onset RA.
METHODS: Baseline data was analyzed from the Study
of New Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM),
a five-year prospective, longitudinal, inception cohort
study to document long-term functional, clinical, and hu-
manistic outcomes and patterns of treatment in patients
with new onset RA. Baseline data collection consisted of
physician and patient surveys. Physicians assessed swol-
len (SJ) and tender/painful joints (TJ) while patients re-
ported painful joint (PJ). Physician’s SJ and TJ consisted
of examination in 64 and 66 joints, respectively. Patient’s
PJ was assessed in 16 joint areas with use of a manne-
quin. The Pearson product moment correlation coeffi-
cient was calculated for SJ, TJ, and PJ counts. RESULTS:
One hundred and seven patients completed the baseline
survey. Mean age of the sample was 55 6 15 years; 79%
were female; 80% were Caucasian. Mean joint counts were
12.6 (SE 5 0.9) SJ, 14.0 (SE 5 1.3) TJ, and 6.6 (SE 5
0.4) PJ. Patient-reported PJ correlated with physician-
Strategy Cost QALY $QALY
Quick Relievers alone $5,185 6.77 —
1ICS in moderate disease $5,961 6.84 $10,300
1ICS in mild disease $7,616 6.93 dominated
1ICS in mild/mod. disease $8,392 7.00 $15,000
reported SJ (r 5 0.22, p 5 0.023) and TJ (r 5 0.55, p ,
0.001). CONCLUSION: Higher correlation was observed
between PJ and TJ compared to SJ. Patient, self-reported
joint counts may be a useful surrogate of joint activity in
the absence of physician assessment. However, caution
should be taken given that the accuracy of patient, self-
reported joint counts still needs further evaluation. Five-
year follow-up of this population will provide further in-
sight on the sensitivity to change for both patient and
physician reported joint counts as it relates to disease ac-
tivity.
PAM2
AN ECONOMIC EVALUATION OF 
OSTEOPOROSIS MEDICATION USE PATTERNS 
IN A MANAGED CARE ORGANIZATION: A TIME 
TO FRACTURE ANALYSIS
Chen KS1, White TJ2, Chang E2
1University of Southern California, Los Angeles, CA, USA; 
2Prescription Solutions, Costa Mesa, CA, USA
Osteoporosis affects approximately 24 million Americans
and accounts for an estimated annual direct medical costs
of over $13.8 billion. An economic analysis that evalu-
ates the effectiveness of osteoporosis medications for pre-
vention of bone fractures in a naturalistic setting has not
been formally conducted. OBJECTIVES: To compare
differences among four therapeutic alternatives [estrogen
replacement therapy (ERT), raloxifene, nasal calcitonin,
and alendronate] with respect to health care costs (phar-
macy, medical, and total), and time to fracture. METH-
ODS: Retrospective pharmacy and medical claims data
from a large managed care organization were analyzed.
Patients were included if they were diagnosed with os-
teoporosis and newly initiated on medication between
1/1/98–12/31/98. All patients were followed for exactly 1
year. Cost data was log-transformed to correct for skew-
ness. ANCOVA was conducted to compare total health
care costs; Cox Proportional Hazard Model was per-
formed to compare the risk of fracture. Total health care
costs was defined as all osteoporosis-related services cov-
ered. RESULTS: There were 12,757 female patients iden-
tified for the analysis and the average age was 70(S.D. 5
10). A total of 1,721(13.5%) patients had a fracture after
initiation of drug therapy. After adjusting for age, prior
medication costs, prior fracture event, and comorbidities,
adjusted means (95%CI) of log-transformed total health
care costs was lowest for ERT 5.87(5.84–5.90), com-
pared to raloxifene 6.32(6.19–6.46), alendronate
6.55(6.51–6.59) and calcitonin 7.20(6.61–7.80). Com-
pared to calcitonin, the adjusted hazard ratios (95%CI)
for a fracture were 0.174(0.078–0.39) for ERT,
0.175(0.078–0.39) for alendronate, and 0.160(0.068–
0.377) for raloxifene. CONCLUSIONS: In this popula-
tion, ERT was associated with statistically significant
lower total health care costs compared to raloxifene, al-
endronate, and calcitonin. Raloxifene was associated
with statistically significant lower total health care costs
